The first clinical trial of high dose of baclofen for treatment of alcohol dependence has been published in a medical journal (Ameisen O / R. de Baurepaire, Annales medico-psychological, January 2010). This test, which focused on 60 patients for whom conventional treatments had failed, demonstrating that high-dose baclofen suppresses alcohol dependence and consumption in 88% of these patients. The removal of alcohol dependence was described for the first time in the medical literature in 2004 by Prof. Ameisen that, based on animal models of addiction withdrawal, had managed to completely remove his own addiction to alcohol, self-administering high dose of baclofen. Since then, the abolition of alcohol dependence using high-dose baclofen, has been reproduced and published in the medical literature and in hundreds of patients in Europe and the United States. As in animals, baclofen is, in humans, the only drug for which the complete removal of pathological desire to consume alcohol is established. Other drugs, naltrexone (naltrexone) and its derivative nalmefene (Revex), acamprosate (acamprosate, Campral), topiramate (Epitomax) etc ... only suppress the urge. The link to the medical article is:
Suppression de la dépendance à l’alcool et de la consommation d’alcool par le baclofène à haute dose : un essai en ouvert - EM|consulte Suppression de la dépendance à l’alcool et de la consommation d’alcool par le baclofène à haute dose : un essai en ouvert - EM|consulte
The results show that three months of treatment, 88% of patients have completely stopped or significantly reduced their intake of alcohol and that most of them have become indifferent to the alcohol without effort. The doses of baclofen were required vary from one patient to another, ranging from 15mg/jour to 300mg/jour, with an average of 145mg/jour. Approximately two thirds of patients required a dose greater than that permitted 80mg / d.
Comment